Lv54
1038 积分 2024-06-06 加入
GLP-1-based therapies for diabetes, obesity and beyond
13天前
已完结
Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis
13天前
已完结
Definition and diagnostic criteria of clinical obesity
19天前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
20天前
已完结
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial
2个月前
已完结
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
2个月前
已完结
BIO89-100, a novel glycoPEGylated FGF21 Analog, Demonstrates Triglyceride Reduction and Broad Metabolic Effects in Spontaneously Diabetic Obese Cynomolgus Monkeys
2个月前
已关闭
Bridging Studies in Preclinical Pharmaceutical Safety Assessment
3个月前
已关闭
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
3个月前
已完结
皖公网安备34019202002308
